24 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
32
Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
University of Tennessee Health Science Center
32
Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead.
Ono Pharmaceutical
10
Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor.
The University of Tennessee Health Science Center
10
Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists.
The University of Utah
40
Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts.
F. Hoffmann-La Roche
2
Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents.
University of Tennessee Health Science Center
7
Structure-based drug design identifies novel LPA3 antagonists.
The University of Memphis
10
Identification of non-lipid LPA3 antagonists by virtual screening.
The University of Memphis
36
Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development.
Jss Academy of Higher Education and Research
4
Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors.
The University of Utah
14
Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors.
University of Tennessee Health Science Center
12
Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.
University of Tennessee Health Science Center
24
Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.
University of Tennessee Health Science Center
6
Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA
Universidad Complutense De Madrid
10
Structure-activity relationships of fluorinated lysophosphatidic acid analogues.
The University of Utah
24
A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist.
University of Virginia
9
Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid.
Oxford University
28
Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist.
University of Virginia
23
Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.
X-Chem
2
Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.
University of Virginia
